[Clinical and immunological signs of retinal lesions and possibilities of their correction by drugs in patients with chronic diffuse liver diseases of viral etiology and carriers of Australia antigen].
A total of 133 subjects aged 15 to 55 were followed up, the main group (n = 87), patients with chronic diffuse diseases of the liver caused by hepatitis B virus, and two reference groups, 26 patients with uveitis and 20 normal subjects, 13 and 4 subjects of each group, respectively, were Australian antigen (HBsAg) carriers. Functional disorders of the retina were detected in 93.2% of group 1 patients, as well as intensified local (tears) and total system (blood) autoimmune reactions to tissue-specific retinal S-antigen (mol.mass 48 kD). An increased detection rate of antibodies to S-antigen and its higher titers were found in healthy virus carriers as compared to HBsAg-seronegative donors. These data may be regarded as evidence of an increased risk of uveoretinal pathology in subjects infected with hepatitis B virus, this being confirmed by a higher incidence (50%) of latent virus carriership in the group of patients with uveoretinitis. Stabilizing effect of cavinton in functional changes of the retina was revealed, this recommending this drug for combined therapy of patients with chronic diffuse diseases of the liver and for prevention of ocular diseases. The majority of the examinees in whom retinal abnormalities were found being young, the authors draw attention to the social aspect of the problem.
Slepova
O S
OS
Kushnir
V N
VN
Zaĭtseva
N S
NS
Titarenko
Z D
ZD
Dumbrava
V A
VA
D000293:Adolescent; D000328:Adult; D000941:Antigens / Q000032:analysis; D019393:Arrestin; D001324:Autoantigens / Q000032:analysis; D002353:Carrier State; D015828:Eye Infections, Viral / Q000517:prevention & control*; D005136:Eye Proteins / Q000032:analysis; D005260:Female; D006509:Hepatitis B / Q000150:complications* / Q000276:immunology; D006514:Hepatitis B Surface Antigens / Q000032:analysis; D006801:Humans; D008297:Male; D008875:Middle Aged; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D012164:Retinal Diseases / Q000209:etiology* / Q000276:immunology / Q000517:prevention & control; D014605:Uveitis / Q000209:etiology / Q000276:immunology / Q000517:prevention & control; D014748:Vinca Alkaloids / Q000627:therapeutic use*
D000941:Antigens; D019393:Arrestin; D001324:Autoantigens; D005136:Eye Proteins; D006514:Hepatitis B Surface Antigens; D010726:Phosphodiesterase Inhibitors; D014748:Vinca Alkaloids; C013983:vinpocetine
Kliniko-immunologicheskie priznaki porazheniia setchatki i vozmozhnosti ikh farmakokorrektsii u bol'nykh s khronicheskimi diffuznymi zabolevaniiami pecheni virusnoĭ étiologii i nositeleĭ avstraliĭskogo antigena.